<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Etty Hary Kusumastuti</style></author><author><style face="normal" font="default" size="100%">Stephanie Natasha Djuanda</style></author><author><style face="normal" font="default" size="100%">Grace Ariani</style></author><author><style face="normal" font="default" size="100%">Gondo Mastutik</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Correlation of N-Cadherin and MMP-9 Expression with Regional Nodal Metastasis in Laryngeal Squamous Cell Carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Laryngeal cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Metastasis</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">N stages</style></keyword><keyword><style  face="normal" font="default" size="100%">N-cadherin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">679-683</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; In laryngeal carcinoma, regional nodal metastasis serves as a significant prognostic factor. A special biomarker is needed to predict the status of nodal metastases. N-cadherin, a binding protein, aids in cell migration and enabling tumor cells to spread to new locations. The involvement of matrix metalloproteinase-9 (MMP-9) in metastasis includes fostering the dissemination of tumor cells from the primary tumor and enhancing tumor cell motility. &lt;strong&gt;Objective:&lt;/strong&gt; This study seeks to explore the distinctions and relationships in N-cadherin and MMP-9 expression among patients with laryngeal squamous cell carcinoma at various N stages. &lt;strong&gt;Methods:&lt;/strong&gt; Employing a cross-sectional approach, this study conducted an analytic observational investigation on formalin-fixed paraffin-embedded patients whose histopathological diagnosis is laryngeal squamous cell carcinoma in the Pathology Laboratory of Dr. Soetomo Regional Public Hospital in 2018–2021. The samples were divided into N stages based on radiological imaging from the CT scan. Immunohistochemistry examinations were performed using N-cadherin and MMP-9 antibodies and scored using the immunoreactive score (IRS), based on percentage and intensity. The differences in expression and correlation between N-cadherin and MMP-9 were analyzed using statistical tests. &lt;strong&gt;Results:&lt;/strong&gt; Statistical insignificance was observed in N-cadherin expression at various N stages (p = 0.099). There were significant differences in MMP-9 expressions at various N stages (p = 0.0006338). There was no correlation between N-cadherin and MMP-9 expression at various N stages in laryngeal squamous cell carcinoma (p = 0.0638, rs = 0.27). &lt;strong&gt;Conclusion:&lt;/strong&gt; In laryngeal squamous cell carcinoma, MMP-9 serves as a predictor for lymph node metastasis, which, if present, deteriorates the patient's prognosis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">679</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Etty Hary Kusumastuti&lt;sup&gt;1,2&lt;/sup&gt;*, Stephanie Natasha Djuanda&lt;sup&gt;1,2&lt;/sup&gt;, Grace Ariani&lt;sup&gt;1,2&lt;/sup&gt;, Gondo Mastutik&lt;sup&gt;2&lt;/sup&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Dr Soetomo Academic General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Worawat Songjang</style></author><author><style face="normal" font="default" size="100%">Arunya Jiraviriyakul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Honokiol and Magnolol Induce Apoptosis and Cell Cycle Arrest in Human Ovarian Cancer Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Honokiol</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnolol</style></keyword><keyword><style  face="normal" font="default" size="100%">Metastasis</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian Cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Proliferation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">September 2019</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">1114-1123</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Ovarian cancer is a major cause of cancer-related death among women. The growth, persistence, and cancer metastasis are causes of poor prognosis and high mortality rate. Honokiol and magnolol are derivative compounds extracted from the root and stem bark of &lt;em&gt;Magnolia officinalis&lt;/em&gt;. Many studies have reported that honokiol and magnolol have anti-tumour effects on various types of cancer. The present study investigates the anti-tumour effect of these compounds on human ovarian cancer. &lt;strong&gt;Methods:&lt;/strong&gt; Ovarian cancer cell lines, SKOV3 and ES-2 cells were tested with honokiol and magnolol to determine their responses including the cytotoxicity, cell proliferation, induction of cell apoptosis and metastasis ability. &lt;strong&gt;Result:&lt;/strong&gt; The results indicate that low concentrations of honokiol and magnolol suppressed the proliferation of ovarian cancer cells through induction of cell cycle arrest at G0/G1 and down-regulation of the cyclin D1 protein. These compounds also exhibited an anti-metastatic ability mediated by inhibiting migration, adhesion, and MMP activities. Additionally, high concentrations of honokiol and magnolol could activate cell death associated with the apoptosis signalling pathway, either along an intrinsic or extrinsic pathway. &lt;strong&gt;Conclusion: &lt;/strong&gt;The data provides evidence that honokiol and magnolol have potential anti-tumour properties and minimal toxicity on normal cells, and could therefore be applied in the treatment of ovarian cancer.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1114</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Worawat Songjang&lt;sup&gt;1&lt;/sup&gt; and Arunya Jiraviriyakul&lt;sup&gt;2&lt;/sup&gt;* &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Biomedical Science Graduated School, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Medical technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, THAILAND.&lt;/p&gt;
</style></auth-address></record></records></xml>